Paul Hastings Advised Corcept Therapeutics in its $145.4 Million Tender Offer

Paul Hastings LLP advised Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, in its $145.4 million issuer tender offer for common stock.

Partners Jeff Hartlin and Samantha Eldredge led the Paul Hastings team, which also included associates Jenna Barba and Nina John.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment and real estate, Paul Hastings is a premier law firm providing superior intellectual capital and execution globally to the world’s leading investment banks, asset managers and corporations.